Access
To read this story in full you will need to login or make a payment (see right).
Editorial
Nature 423, 207 (15 May 2003) | doi:10.1038/423207b
Gene patents and the public good
Top of page
Abstract
A race to claim patents on the SARS virus raises questions about the patent system's ability to cope with genomics.
Barely had the last nucleotide in the genetic code of the SARS coronavirus been read when the race to claim intellectual rights to the sequence began. And among those filing was the US Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, in what was essentially a pre-emptive strike (see page 214).
To read this story in full you will need to login or make a payment (see right).